


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**


Claims 1-2 (Cancelled)

Claim 3 (Currently Amended) The A compound of ~~claim 2~~ comprising



or a pharmaceutically acceptable salt or an ester thereof.

Claim 4 (Original) The compound of claim 3 consisting of



Claims 5-6 (Cancelled)

Claim 7 (Currently Amended) The compound of claim 4 3 comprising 4-{2-[(R)-2-[(E)-3-Hydroxy-4-phenyl-but-1-enyl]-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or

4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid,  
or a pharmaceutically acceptable salt or an ester thereof.

Claim 8 (Original) The compound of claim 4 3 consisting of  
4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid methyl ester, or  
4-{2-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-ethylsulfanyl}-butyric acid.

Claim 9 (Currently Amended) A method comprising administering an effective amount of a compound of claim 3 to a mammal, said method being effective in treating glaucoma, ~~preventing glaucoma in individuals with ocular hypertension,~~ or ~~treating~~-intraocular hypertension.

Claim 10 (Cancelled)